医学影像可检测抗PD1治疗患者的免疫相关不良事件
结果显示影像学总体检出率为74%(95%CI 63-84%),其中18F-FDG PET/CT和MRI均为83%,CT为79%,超声为70%,X线为40%。
要点
- 医学影像可检出74%的irAE,辅助临床管理
- PET/CT、MRI和CT对irAE检出率较高
- 肺炎、结肠炎和垂体炎影像检出率均达100%
核心结论
- 医学影像在抗PD1治疗患者中可检测74%的irAE,并有助于指导特异性管理。
主要发现
- 共分析74次医学影像检查(人均1.4次),检出55个irAE。
- irAE总体检出率为74%(95%CI 63-84%)。
- 18F-FDG PET/CT检出率为83%(n=10/12),MRI为83%(n=5/6),CT为79%(n=19/24),超声为70%(n=19/27),X线为40%(n=2/5)。
关键数值与推荐
- 按部位/类型检出率:肺/纵隔100%(n=7/7),小肠结肠炎100%(n=8/8),垂体炎100%(n=3/3),甲状腺炎75%(n=15/20),肝炎67%(n=2/3),关节痛或关节炎40%(n=2/5),胰腺28%(n=2/7)。
临床怎么用
- 在抗PD1治疗患者的影像评估中,除评估肿瘤反应外,应关注irAE的影像学征象,以辅助早期识别和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed death receptor-1 blocking antibodies (anti-PD1) are a new standard of care in many cancer types. Patients benefit from improved survival but have the risk of immune-related adverse events (irAE). We evaluated if medical imaging procedures, used for anti-tumour response assessment, can detect irAEs. MATERIALS AND METHODS: All consecutive patients treated with anti-PD1 and with a medical imaging acquisition performed within 2 weeks with irAEs ≥2 were retrospectively included. Data were gathered from June 2014 to February 2017, and a central review was performed. The primary and secondary end-points were i) to evaluate the overall detection rate of irAEs by medical imaging and ii) to provide a comprehensive radiological description of irAEs. RESULTS: Fifty-three patients (31 women, 22 men; average age: 61 years) were included. The primary tumour was melanoma (n = 32), lung cancer (n = 18) and other (n = 3). Patients were treated with nivolumab (n = 27) or pembrolizumab (n = 26). Of 74 medical imaging procedures analysed (ratio = 1.4 medical imaging per patient), 55 irAE were detected. The detection rate was overall: 74% (95 confidence interval: 63-84%), positron emission tomography with 18F-fludeoxyglucose integrated with computed tomography (18F-FDG PET/CT): 83% (n = 10/12), magnetic resonance imaging: 83% (n = 5/6), computed tomography scan: 79% (n = 19/24), ultrasonography: 70% (n = 19/27), standard X-rays: 40% (n = 2/5), lung/mediastinum: 100% (n = 7/7), enterocolitis: 100% (n = 8/8), hypophysitis: 100% (n = 3/3), thyroiditis: 75% (n = 15/20), hepatitis: 67% (n = 2/3), arthralgia or arthritis: 40% (n = 2/5) and pancreas: 28% (n = 2/7). CONCLUSION: Medical imaging detected 74% of irAE in patients treated with anti-PD1. Beyond response assessment, medical imaging can detect irAE and guide towards specific management. We described the most frequent sites and patterns of imaging findings.
引用
- Mekki A, Dercle L, Lichtenstein P, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer. 2018. PMID: 29698933. doi:10.1016/j.ejca.2018.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。